The latest price target for Orchestra BioMed Hldgs (NASDAQ:OBIO) was reported by Barclays on January 2, 2025. The analyst firm set a price target for $16.00 expecting OBIO to rise to within 12 months (a possible 192.50% upside). 7 analyst firms have reported ratings in the last year.

The latest analyst rating for Orchestra BioMed Hldgs (NASDAQ:OBIO) was provided by Barclays, and Orchestra BioMed Hldgs initiated their overweight rating.

There is no last upgrade for Orchestra BioMed Hldgs

There is no last downgrade for Orchestra BioMed Hldgs.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Orchestra BioMed Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Orchestra BioMed Hldgs was filed on January 2, 2025 so you should expect the next rating to be made available sometime around January 2, 2026.

While ratings are subjective and will change, the latest Orchestra BioMed Hldgs (OBIO) rating was a initiated with a price target of $0.00 to $16.00. The current price Orchestra BioMed Hldgs (OBIO) is trading at is $5.47, which is within the analyst’s predicted range.